Supplemental Table 1 Doses and number of users for each preparation analyzed.
CEE <
0.625mg n % CEE>
0.625mg n % Oral
E2 n % Trans-
Dermal n % Other E1 Sulphate Dom
n %
0.125mg 16 1.5 0.9mg 680 42.0 0.5mg 157 9.0 0.05mg 883 69 0.3mg 37 2.3 0.3mg 1064 98.5 1.25mg 909 56.2 1 mg 1323 76.0 0.07mg 1 0.1 0.625m 1156 71.9
2.5mg 29 1.8 2 mg 221 12.7 0.10mg 211 17 1.25mg 302 18.8
? 39 2.2 ? 187 15 2.5mg 61 3.8
? 53 3.3
E2 = estradiol E1=Estrone
Supplemental Table 2. Year 3 Blood Pressure by 0.625mg CEE versus Other Doses
Outcome low dose CEE (n=965) conventional CEE (n=11166) high Dose CEE
(n=1378) Trend p-valuea Year 3 Systolic
Blood Pressure Mean (SD) 119.6 (14.8) 120.0 (14.6) 119.6 (14.1)
Model Estimate (95%CI) Estimate (95%CI)
Unadjusted 0.00 (ref) 0.03
Age/Race 0.00 (ref)
Estimate (95%CI) 0.10 (-0.60 to 0.80)
0.14 (-0.56 to 0.85) 0.03 Multivariateb
-1.16 (-1.99 to -0.34) -1.14 (-1.96 to -0.31)
-1.01 (-1.83 to -0.18) 0.00 (ref) -0.32 (-1.04 to 0.39) 0.34
Year 3 Diastolic
Blood Pressure Mean (SD) 70.8 (8.6) 71.8 (8.4) 72.2 (8.2)
Model Estimate (95%CI) Estimate (95%CI)
Unadjusted 0.00 (ref) 0.20
Age/Race 0.00 (ref)
Estimate (95%CI) 0.07 (-0.35 to 0.48)
0.06 (-0.36 to 0.47) 0.29 Multivariateb
-0.37 (-0.86 to 0.12) -0.31 (-0.80 to 0.18)
-0.28 (-0.76 to 0.21) 0.00 (ref) -0.09 (-0.51 to 0.34) 0.65
All models are adjusted for baseline systolic blood pressure, diastolic blood pressure, CVD (MI, CABG, PTCA, or stroke), 5-year age group, and year 3 treated hypertension
a
Trend p-value from a separate model with outcome as a function of linear trend over CEE dose levels (low = 1, conventional = 2, high = 3)
b
Multivariate models are additionally adjusted for age, race/ethnicity, smoking, physical activity, BMI, history of treated
diabetes, history of pills for high cholesterol, alcohol, hysterectomy, oophorectomy, and education.
Supplemental Table 3. Treated Hypertension by Direct comparison of 0.625mg CEE versus Other Preparations, By Subgroups
Subgroup 0.625mgl CEE
(n=12657) oral estradiol (n=1740) transdermal (n=1282) other estrone sulphate
dominant (n=1609) Interacti on Events An
n %
HR (95%
CI) Events An
n % HR (95% CI) Events An
n % HR (95% CI) Events An
n % HR (95% CI) p-value
HT Type 0.84
E-Alone 981 3.4 1.00 (ref) 125 2.9 0.91 (0.76 to
1.10) 129 3.0 0.95 (0.79 to
1.15) 118 3.0 0.88 (0.73 to 1.07) E + P 951 2.6 1.00 (ref) 99 2.0 0.86 (0.70 to
1.06) 53 2.1 0.83 (0.63 to
1.09) 103 2.3 0.89 (0.73 to 1.09) Years Since
Menopause 0.59
<10 669 2.4 1.00 (ref) 101 2.1 0.93 (0.75 to
1.15) 67 2.0 0.82 (0.63 to
1.05) 72 2.0 0.85 (0.67 to 1.08) ≥10 1263 3.3 1.00 (ref) 123 2.7 0.86 (0.71 to
1.03) 115 3.1 0.98 (0.81 to
1.19) 149 3.0 0.91 (0.76 to 1.07) Years of Current
HT Use 0.35
<5 612 2.6 1.00 (ref) 102 2.4 0.94 (0.76 to
1.16) 62 2.4 0.91 (0.70 to
1.18) 85 2.7 1.04 (0.83 to 1.31) ≥5 1315 3.1 1.00 (ref) 120 2.4 0.85 (0.70 to
1.02) 120 2.8 0.92 (0.76 to
1.11) 136 2.6 0.81 (0.68 to 0.97) Age at
Screening 0.25
<60 712 2.3 1.00 (ref) 121 2.2 0.95 (0.78 to
1.15) 90 2.2 0.87 (0.70 to
1.09) 79 1.9 0.81 (0.64 to 1.03) 60 – 69 864 3.1 1.00 (ref) 81 2.7 0.85 (0.68 to
1.07) 74 3.0 0.91 (0.72 to
1.15) 98 2.9 0.91 (0.74 to 1.12) ≥70 356 4.4 1.00 (ref) 22 2.8 0.65 (0.42 to
1.00) 18 4.6 1.01 (0.63 to
1.63) 44 4.2 0.98 (0.71 to 1.33) Progestogen
Type (E+P Participants Only)
0.20
Provera / MPA 838 2.5 1.00 (ref) 72 1.8 0.78 (0.62 to
1.00) 45 2.2 0.92 (0.68 to
1.24) 82 2.2 0.86 (0.69 to 1.08) Other/Unknown 109 2.9 1.00 (ref) 27 3.0 1.15 (0.75 to
1.75) 8 1.4 0.53 (0.26 to
1.09) 21 2.6 0.90 (0.56 to 1.43)
